Johnson & Johnson (NYSE:JNJ) Shares Sold by GYL Financial Synergies LLC

GYL Financial Synergies LLC lowered its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 4.9% during the third quarter, Holdings Channel.com reports. The fund owned 8,951 shares of the company’s stock after selling 459 shares during the quarter. GYL Financial Synergies LLC’s holdings in Johnson & Johnson were worth $1,462,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD lifted its holdings in Johnson & Johnson by 18.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock valued at $4,370,793,000 after purchasing an additional 3,912,430 shares in the last quarter. Legal & General Group Plc lifted its holdings in Johnson & Johnson by 2.3% in the 2nd quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock valued at $3,344,295,000 after purchasing an additional 421,779 shares in the last quarter. FMR LLC lifted its holdings in Johnson & Johnson by 20.8% in the 2nd quarter. FMR LLC now owns 18,725,049 shares of the company’s stock valued at $3,323,883,000 after purchasing an additional 3,229,032 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Johnson & Johnson by 1.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after purchasing an additional 328,297 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Johnson & Johnson by 0.3% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,163,229 shares of the company’s stock valued at $1,333,545,000 after purchasing an additional 24,505 shares in the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO Robert J. Decker sold 16,928 shares of Johnson & Johnson stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $175.00, for a total value of $2,962,400.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,707,775. The disclosure for this sale can be found here. Insiders sold a total of 233,611 shares of company stock valued at $40,960,735 in the last three months. 0.35% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on JNJ shares. Raymond James decreased their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a report on Wednesday, October 19th. Bank of America reduced their price target on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. Credit Suisse Group began coverage on Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target on the stock. StockNews.com began coverage on Johnson & Johnson in a report on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Finally, Barclays began coverage on Johnson & Johnson in a report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price target on the stock. Seven analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $181.75.

Johnson & Johnson Stock Down 0.5 %

Shares of NYSE:JNJ opened at $168.74 on Monday. The business has a 50-day moving average price of $176.14 and a 200 day moving average price of $171.20. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $441.17 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 3.19 and a beta of 0.56. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.68%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.